Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
M&A, French election relief and renewed talk of reforms to taxes and trade all helped to push European stocks higher Tuesday
Here are Tuesday's top research calls, including downgrades for Amazon and C.R. Bard, and new coverage of CyrusOne and Dow Chemical.